Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$180MCash, Jun 2026
131moCash Runway (est.)
+33%Share Count, 1 Year
Follow BNTC by emailGet an email when BNTC pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BNTC, unsubscribe in one click. Privacy
📣 What BNTC Says Is Next
mid-2027 · “Benitec anticipates initiating the BB-301 pivotal trial in mid-2027.”
Company press release, Sep 14, 2026 · SEC filing
2H · “Benitec remains on track to provide updated interim clinical study results for Cohort 1 patients and Cohort 2 patients in 2H-2026.”
Company press release, May 14, 2026 · SEC filing
2H · “Advancement of Cohort 2 enrollment continues as Patient 1 and Patient 2 were both safely treated with high dose BB-301 in the ongoing Phase 1b/2a clinical study of BB-301; Benitec remains on track to provide updated interim clinical study results in 2H-2026”
Company press release, May 14, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
BNTC reported $180M in cash and short-term investments (as of Jun 30, 2026) and used about $4.1M/quarter in operations, an estimated runway of 130.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:39 · Moderate
Cash runway 131 months
ATM program on file since Sep 2025 +15
Shelf registration (S-3, Sep 2026) +10
Share count +33% in a year +14
Recent financing filings on SEC EDGAR:
Sep 14, 2026 · Shelf registration, up to $200M · S-3
Nov 7, 2025 · Registered direct / best-efforts offering · 424B5
Nov 5, 2025 · Registered direct / best-efforts offering · 424B5
Sep 22, 2025 · Shelf registration with ATM program, up to $125M · S-3
Mar 26, 2025 · Registered direct / best-efforts offering · 424B5
Nov 1, 2024 · Shelf registration with ATM program, up to $125M · S-3
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BNTC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.